Skip to main content
Retour
Watch Compare

Finch Therapeutics Group, Inc.

Qualité des données : 100%
Également cotée sous FNCHQ OTC
FNCH
OTC Manufacturing Chemicals
9,20 €
0,00 € (0,00%)
Cap. Boursière: 14,77 M
Prix
9,20 €
Cap. Boursière
14,77 M
Fourchette du Jour
5,01 € — 11,91 €
Fourchette 52 Semaines
2,00 € — 16,10 €
Volume
71 791
Ouverture 11,90 €
Moyenne 50J / 200J
12,77 €
27,95% below
Moyenne 50J / 200J
12,96 €
29,01% below

Quick Summary

Points Clés

Negative free cash flow of -18,04 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-87,57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-85,20%
En dessous de la moyenne du secteur (-53,41%)
ROIC-35,14%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio3,87
Interest CoverageN/A

Valorisation

PE (TTM)
-1,04
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,04
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,0 -1,5
P/B 1,0 1,6
ROE % -85,2 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -87,57% Revenue Growth (3Y) -92,40%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -14,17 M
ROE -85,20% ROA -29,62%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -18,04 M
ROIC -35,14% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,87
Interest Coverage N/A Asset Turnover 0,00
Working Capital 12,82 M Tangible Book Value 14,22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,04 Forward P/E N/A
P/B Ratio 1,04 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -122,12%
Market Cap 14,77 M Enterprise Value -1,26 M
Per Share
EPS (Diluted TTM) -8,80 Revenue / Share 0,00
FCF / Share -11,24 OCF / Share -11,24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 127,35%
SBC-Adj. FCF -19,60 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2023 FY2022 FY2021
Revenue 107 000,0 861 000,0 18,53 M
Net Income -74,75 M -114,65 M -58,16 M
EPS (Diluted) -46,59 -2,40 —
Gross Profit — — —
Operating Income -83,86 M -115,59 M -59,99 M
EBITDA — — —
R&D Expenses 7,20 M 57,89 M 57,28 M
SG&A Expenses — — —
D&A 1,52 M 5,51 M 2,30 M
Interest Expense — — —
Income Tax -3,46 M 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2022 FY2021
Total Assets 55,37 M 162,94 M 225,37 M
Total Liabilities 32,49 M 67,23 M 23,15 M
Shareholders' Equity 22,89 M 95,71 M 202,22 M
Total Debt 0,0 15,00 M 0,0
Cash & Equivalents 25,12 M 71,04 M 133,48 M
Current Assets 25,85 M 74,55 M 142,55 M
Current Liabilities 4,08 M 14,69 M 14,79 M